<DOC>
	<DOCNO>NCT00467181</DOCNO>
	<brief_summary>The Primary objective reduce incidence postoperative renal dysfunction high-risk subset patient undergoing cardiac surgery cardiopulmonary bypass Fenolopam , selective dopamine-1 receptor agonist . Perioperative renal function observe 3 randomly select group patients-Fenoldopam infusion 0.03 cg/kg/min , Fenoldopam 0.1 mcg/kg/min placebo Secondary objective : correlate Fenoldopam usage postoperative clinical outcome ICU stay , hospital stay , need inotropes/vasopressors , need diuretic , requirement ECF discharge , overall perioperative cost reduction decrease ICU hospital length stay .</brief_summary>
	<brief_title>A Pilot Study Investigate Fenoldopam Usage Prevention Postoperative Renal Dysfunction Patients High Risk Renal Impairment During Cariopulmonary Bypass Cardiac Surgery</brief_title>
	<detailed_description>Although patient undergo cardiac surgery risk renal dysfunction , certain preoperative clinical parameter show place patient particularly high risk postoperative renal demise . These factor include age great 70 ( patient great 80 year particular high risk ) , history New York Heart Association Class 3 4 congestive heart failure , previous coronary artery bypass grafting , pre-operative creatinine level 1.24-1.77 mmol/dL , type I diabetes , preoperative glucose &gt; 166 mmol/dL , cardiopulmonary bypass time &gt; 3 hour , low cardiac output state ( state require intra-aortic balloon pump ( IABP ) cardiac index le 1.5 require 3 inotropic drug ) .1 Recently , interest pharmacologic manipulation peripheral dopamine receptor ( DA1 DA2 ) attempt augment preserve renal function . Goldberg colleague localize DA1 receptor vascular smooth muscle postsynaptic membrane renal , coronary , cerebral , mesenteric , peripheral artery vasculature , proximal convolute tubule , cortical collecting duct nephron.6,7 Stimulation DA1 receptor activate adenylate cyclase cause vascular smooth muscle vasodilation naturesis increase urinary sodium excretion inhibit sodium-potassium ATPase-dependent process proximal convolute tubule thick portion ascend loop Henle.6,8,9 The great effect DA1 receptor activation occur renal vasculature ( mostly afferent arteriole ) 9 , cause increase renal blood flow 35 % normal patient 77 % patient renal vascular disease.10,11 DA2 receptor find renal parenchyma , presynaptic nerve terminal adrenergic nerve sympathetic ganglion , adrenal cortex.10 DA2 receptor activation lead inhibition norepinephrine release ( part negative feedback loop ) inhibition angiotensin II mediate release aldosterone.10,12 With activation DA2 receptor kidney , resultant decrease renal blood flow , decrease glomerular filtration rate , decrease diuresis naturesis observe , effect opposite may offset DA-1 receptor agonism . Mayes colleague show improvement renal function patient undergo CABG `` renal-dose '' dopamine.6 , 13 It theorize dopamine 's inability provide renal protection may due lack specificity DA-1 receptor resultant dose-dependent agonism DA-2 receptor alpha1-adrenergic receptors.6 , 14 , 15 As mention , dopamine 's activation receptor result decrease renal blood flow , glomerular filtration rate , sodium excretion6 , 16 , thereby offset effect DA-1 receptor agonism . Fenoldopam first commercially available selective DA1 receptor agonist . Fenoldopam selective agonist DA1 receptor activity DA2 receptor , alpha adrenergic receptor , beta adrenergic receptor . Currently , Fenoldopam use intravenous infusion hypertensive emergency . When give hypertensive patient dose 0.025-0.5 mcg/kg/min , reduction blood pressure see linear dose dependent manner.9 , 17 , 18 , 19 , 20 Despite reduction perfusion pressure , glomerular filtration rate renal blood flow equivalent even increased.9 , 20 , 21 When give normotensive patient dose 0.03-0.3 mcg/kg/min , Vandana colleague show Fenoldopam significantly increase renal blood flow dose-dependent manner compare placebo change systolic blood pressure minimal change diastolic blood pressure ( 1 mmHg @ 0.3 mcg/kg/min dose ) heart rate ( 14 bpm @ 0.3 mcg/kg/min dose ) . In addition , serious severe side effect even high doses.9 These observation consistent prior study Fenoldopam normotensive22 hypotensive23 patient . Fenoldopam 's lack effect venous capacitance well less role resistance play determine blood pressure normotensive patient may explain negligible effect Fenoldopam blood pressure normotensive subject . This lead theoretic `` renal protection '' provide Fenoldopam dose elicit negligible deleterious effect . As mentioned , Fenoldopam selective DA1 receptor agonist create modification dopamine molecule addition chloride , sulfur , benzene ring.10 These change result agonistic effect exclusively DA-1 receptor DA2 receptor activation direct indirect action alpha beta adrenergic receptors.10 Fenoldopam short half-life 5-10 minute , linear relationship plasma concentration infusion rate , small volume distribution allow rapid intravenous titration.24 These characteristic make Fenoldopam ideal intravenous infusion steady-state plasma concentration achieve within 30-60 minute , steady-state concentration remain constant infusion , negligible concentration ( &lt; 0.2 mcg/L ) 2 hour discontinuation demonstrate Allison colleagues.24 Hepatic clearance Fenoldopam occur conjugation via sulfation glucuronidation.10 Klecker colleague demonstrate drug-drug interaction negligible due parallel pathway metabolism.25 Recent study Garwood colleague Caimmi colleague show preservation renal function perioperative infusion Fenoldopam indicate low creatinine level discharge patient high risk perioperative renal demise.26 , 27 However , prospective randomize control trial yet perform . There also uncertainty reduction serum creatinine level discharge practical benefit term reduce morbidity , reduce length stay , reduce cost , improved clinical performance . In addition , optimal dose Fenoldopam clinical indication yet determine . For pilot study , Fenoldopam infuse 0.03 mcg/kg/min 0.1 mcg/kg/min . These dos choose due proven effectiveness significantly increase renal blood flow minimal effect blood pressure heart rate.9 The goal study evaluate effectiveness Fenoldopam , new selective dopamine-1 receptor agonist , reduction postoperative renal dysfunction high-risk subset patient undergoing cardiac surgery prospective randomize control pilot study . This accomplished infusion Fenoldopam 0.03 mcg/kg/min , 0.1 mcg/kg/min , placebo double blind , randomize , prospective trial postoperative creatinine , urine output , progression renal dysfunction observe . Renal dysfunction define increase serum creatinine great 50 % preoperative value serum creatinine exceed 2.0 mg/dL time postoperatively prior discharge.. In addition , length ICU stay , length hospital stay , ventilator requirement , need diuretic , need perioperative inotropes/vasopressors , need discharge extend care facility examine group . The null hypothesis Fenoldopam reduce incidence postoperative renal dysfunction .</detailed_description>
	<mesh_term>Fenoldopam</mesh_term>
	<criteria>Patients undergo CABG , CABG/valve operation must meet one follow : Age great 70 Preoperative ( within one week ) creatinine &gt; = 1.3 Insulin depenent diabetes NYHA CHF class 3 4 Bypass time anticipate great 3 hour Redo coronary artery bypass graft Low cardiac output state need inotropic agent IABP preoperatively Emergent operation Preopertive liver failure Preopertive acute chronic dialysis dependence Known allergy Fenoldopam Patients usage dopaminergic medication contraindicate Age le 30 Caridac surgery without cardiopulmonary bypass Patients acively participate clinical trial Usage dopaminergic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>cardiac surgery</keyword>
	<keyword>renal dysfunction</keyword>
</DOC>